Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer
The main purpose of this study was to observe the efficacy and safety of treatment with pyrotinib and CDK4/6 inhibitor SHR6390 for HER2-positive metastatic breast cancer.
Metastatic Breast Cancer
DRUG: Pyrotinib combine with SHR6390
Objective Response Rate, CR+PR, from enrollment to progression or death (for any reason), assessed up to 100 months
PFS, Progression-Free Survival, from enrollment to progression or death (for any reason),assessed up to 100 months|OS, Overall Survival, from enrollment to death (for any reason).assessed up to 100 months
The main purpose of this study was to observe the efficacy and safety of treatment with pyrotinib and CDK4/6 inhibitor SHR6390 for HER2-positive metastatic breast cancer.